Hi Endless: IMHO Kynamro most likely will end up being used off-label for more common indications, but the size of the Kynamro market really matter one way or the other for ANP's SP in my opinion.
More directly, as the first treatment of its type to gain approval, the potential approval of Kynamro has been touted by many for the past year to be an indicator confirming the marketability for all second generation antisense genetic therapies - of which ANP has several in clinical pipeline.
I'm not sure exactly how the market will move regarding this though.
